Inogen (INGN) Net Income towards Common Stockholders (2013 - 2026)

Inogen's (INGN) quarterly Net Income towards Common Stockholders came in at -$8.3 million in Q1 2026, down 31.39% year-on-year from -$12.1 million in Q1 2025, and down 199.44% on a QoQ basis from $8.3 million in Q4 2025.

Inogen (INGN) Net Income towards Common Stockholders (2013 - 2026) Analysis & Trends

Inogen (INGN) has 14 years of Net Income towards Common Stockholders data on file, last reported at -$8.3 million in Q1 2026.

  • On a quarterly basis, Net Income towards Common Stockholders fell 31.39% year-over-year to -$8.3 million in Q1 2026; TTM through Mar 2026 was -$10.7 million, a 49.95% increase from a year earlier, with the FY2025 full-year figure at -$8.7 million, up 70.33% from the prior year.
  • Net Income towards Common Stockholders for Q1 2026 stood at -$8.3 million, down from $8.3 million in the prior quarter.
  • Over the last five years, Net Income towards Common Stockholders for INGN reached as high as $72.5 million in Q4 2023 and fell as low as -$55.8 million in Q4 2022.
  • Historically, Net Income towards Common Stockholders has averaged -$7.8 million across 5 years, with a median of -$6.3 million in 2025.
  • Across the five-year window, Net Income towards Common Stockholders slumped 1314.18% in 2022 and soared 342.69% in 2025, its largest moves.
  • Year by year, Net Income towards Common Stockholders stood at -$55.8 million in 2022, then soared by 229.8% to $72.5 million in 2023, then tumbled by 104.74% to -$3.4 million in 2024, then surged by 342.69% to $8.3 million in 2025, then slumped by 199.44% to -$8.3 million in 2026.
  • Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$8.3 million in Q1 2026, $8.3 million in Q4 2025, and -$5.9 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Abbott Laboratories 182.32 Bn 175.02 Bn 6.27 Bn 1.08 Bn
2 Stryker 128.75 Bn 125.88 Bn 3.81 Bn 745.00 Mn
3 Medtronic 107.83 Bn 98.61 Bn 6.41 Bn 1.26 Bn
4 Boston Scientific 67.61 Bn 66.15 Bn 3.61 Bn 1.34 Bn
5 Edwards Lifesciences 48.13 Bn 44.45 Bn 1.29 Bn -
6 Dexcom 28.26 Bn 27.14 Bn 750.30 Mn 199.50 Mn
7 GE HealthCare Technologies 27.78 Bn 25.50 Bn 1.98 Bn 411.00 Mn
8 Smith & Nephew 26.99 Bn 26.41 Bn - -
9 Koninklijke Philips 23.92 Bn 20.80 Bn 2.07 Bn 176.78 Mn
10 Inogen 173.63 Mn 63.46 Mn 37.86 Mn -8.29 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -8.29 Mn
Dec 31, 2025 8.33 Mn
Sep 30, 2025 -5.95 Mn
Jun 30, 2025 -4.76 Mn
Mar 31, 2025 -6.31 Mn
Dec 31, 2024 -3.43 Mn
Sep 30, 2024 -5.96 Mn
Jun 30, 2024 -5.59 Mn
Mar 31, 2024 -14.58 Mn
Dec 31, 2023 72.46 Mn
Sep 30, 2023 -45.71 Mn
Jun 30, 2023 -9.83 Mn
Mar 31, 2023 -20.35 Mn
Dec 31, 2022 -55.83 Mn
Sep 30, 2022 -9.51 Mn
Jun 30, 2022 -2.84 Mn
Mar 31, 2022 -13.76 Mn
Dec 31, 2021 -22.56 Mn
Sep 30, 2021 12.28 Mn
Jun 30, 2021 4.97 Mn